尼莫迪平纳米颗粒:一种有前途的方法来治疗眼
Doaa N Maria1,2, Sara N Maria1,2,3, Monica M Jablonski1,3
1Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Pharmaceutics
|November 27, 2025
概括
新的尼莫迪平 (NMD) 基托桑纳米颗粒 (NMD-CS NPs) 提供了一个有前途的玻璃眼治疗方法. 与临床前模型中的现有治疗方法相比,这些NMD-CS NP显著改善了眼内压力 (IOP) 的降低和持续时间.
科学领域:
- 眼科和制药科学 眼科和制药科学
- 纳米技术在药物输送中的应用
背景情况:
- 青光眼是不可逆转的失明的主要原因,需要有效的眼内压力 (IOP) 降低治疗.
- 局部用尼莫迪平 (NMD),一种通道阻塞剂,已显示出降低内血压的潜力,但其疗效需要提高.
- 开发像纳米颗粒这样的先进药物输送系统可以改善现有药物的治疗效果.
研究的目的:
- 开发和表征尼莫迪平基托桑纳米颗粒 (NMD-CS NPs) 以提高IOP降低功效.
- 评估NMD-CS NP眼滴在体外和体内表现作为潜在的玻璃眼瘤治疗.
主要方法:
- 使用自发乳化溶剂扩散方法与各种基托类型 (CMCS,LCS,MCS) 制定了NMD-CS NP.
- 配方被优化并根据颗粒大小,PDI,泽塔潜力,DSC,FTIR和封装效率进行了表征.
- 在实验室释放,细胞毒性,经角膜透性和体内内血压降低效应被评估为优化的NMD-CS NP眼药.
主要成果:
- 优化的NMD-CS NPs表现出有利的物理化学特性,包括小颗粒大小和狭窄分布.
- NMD-CS NP眼滴显示持续的药物释放,Higuchi非Fickian扩散机制,以及显著增强的角膜透性 (79.41%).
- 在体内研究表明,NMD-MCS NP眼滴提供了优越的IOP降低和较长的持续时间,而不是Timolol马莱酸盐.
结论:
- NMD-CS NP眼滴代表了一种有希望的,无毒的制剂,用于治疗青光眼.
- 开发的纳米颗粒显著提高了尼莫迪平在IOP控制方面的治疗潜力.
- 这些发现支持NMD-CS NP眼滴作为一种新的临床前玻璃眼瘤治疗的进展.
相关概念视频
01:27Open Angle Glaucoma: Treatment
938
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
938
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:25Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
01:22Drug Delivery: Miscellaneous Routes
697
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
697
01:23Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K